medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2020, Number 2

<< Back Next >>

Acta Med 2020; 18 (2)

Benign mammary pathology as a finding in reductive mastoplasty

Zozaya MX, Escobedo BL, Moedano RK, Balanzá LR, García VM

Language: Spanish
References: 23
Page: 140-145
PDF size: 181.51 Kb.


ABSTRACT

Objective: To assess the incidence of benign breast disease (BBD) in pathological specimens of patients undergoing reductive mastoplasty (RM). We studied the pathology reports of patients undergoing RM in a period of 10 years. The association between certain variants and the presence of BBD was analyzed. Of the total 314 patients, 136 (43.3%) presented BBD. The most common lesion was fibrocystic mastopathy (47.7% n = 65), representing 60.3% (n = 41 p = 0.004) of lesions in patients older than 40 years. The second most common lesion was ductal hyperplasia without atypia (46.3% n = 63), predominating in those under 40 years. Fibroadenomas were the most common lesions in those under 40 years (p = 0.002). 82.35% (n = 14 p = 0.004) of microcalcifications were in women older than 40 years. Conclusions: We found a relationship between age and type of injury. The incidence of BBD after RM in this study was 43.3%, percentage below 76.2% reported in the literature. This study helps us increase awareness in the medical community about the possible presence of lesions in the pathological specimen after elective breast surgery in healthy patients.


REFERENCES

  1. Kececi Y, Tasli FA, Yagcı A, Sır E, Canpolat S, Vardar E. Histopathologic findings in breast reduction specimens. J Plast Surg Hand Surg. 2014; 48 (2): 122-125.

  2. Tadler M, Vlastos G, Pelte MF, Tille JC, Bouchardy C, Usel M et al. Breast lesions in reduction mammaplasty specimens: a histopathological pattern in 534 patients. Br J Cancer. 2014; 110 (3): 788-791.

  3. Ambaye AB, MacLennan SE, Goodwin AJ, Suppan T, Naud S, Weaver DL. Carcinoma and atypical hyperplasia in reduction mammaplasty: increased sampling leads to increased detection. A prospective study. Plast Reconstr Surg. 2009; 124 (5): 1386-1392.

  4. Merkkola-von Schantz PA, Jahkola TA, Krogerus LA, Hukkinen KS, Kauhanen SM. Should we routinely analyze reduction mammaplasty specimens? J Plast Reconstr Aesthet Surg. 2017; 70 (2): 196-202.

  5. Clark CJ, Whang S, Paige KT. Incidence of precancerous lesions in breast reduction tissue: a pathologic review of 562 consecutive patients. Plast Reconstr Surg. 2009; 124 (4): 1033-1039.

  6. Carlson GW. The management of breast cancer detected by reduction mammaplasty. Clin Plast Surg. 2016; 43 (2): 341-347.

  7. Petit JY, Rietjens M, Contesso G, Bertin F, Gilles R. Contralateral mastoplasty for breast reconstruction: a good opportunity for glandular exploration and occult carcinomas diagnosis. Ann Surg Oncol. 1997; 4 (6): 511-515.

  8. Boice JD Jr, Friis S, McLaughlin JK, Mellemkjaer L, Blot WJ, Fraumeni JF Jr et al. Cancer following breast reduction surgery in Denmark. Cancer Causes Control. 1997; 8 (2): 253-258.

  9. Baasch M, Nielsen SF, Engholm G, Lund K. Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer. 1996; 73 (7): 961-963.

  10. Brown MH, Weinberg M, Chong N, Levine R, Holowaty E. A cohort study of breast cancer risk in breast reduction patients. Plast Reconstr Surg. 1999; 103 (6): 1674-1681.

  11. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985; 312 (3): 146-151.

  12. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med. 2015; 372 (1): 78-89.

  13. Desouki MM, Li Z, Hameed O, Fadare O, Zhao C. Incidental atypical proliferative lesions in reduction mammoplasty specimens: analysis of 2498 cases from 2 tertiary women’s health centers. Hum Pathol. 2013; 44 (9): 1877-1881.

  14. Colwell AS, Kukreja J, Breuing KH, Lester S, Orgill DP. Occult breast carcinoma in reduction mammaplasty specimens: 14-year experience. Plast Reconstr Surg. 2004; 113 (7): 1984-1988.

  15. Dotto J, Kluk M, Geramizadeh B, Tavassoli FA. Frequency of clinically occult intraepithelial and invasive neoplasia in reduction mammoplasty specimens: a study of 516 cases. Int J Surg Pathol. 2008; 16 (1): 25-30.

  16. Slezak S, Bluebond-Langner R. Occult carcinoma in 866 reduction mammaplasties: preserving the choice of lumpectomy. Plast Reconstr Surg. 2011; 127 (2): 525-530.

  17. 17 Aytac B, Sahsine T, Erturk FY, Kahveci R, Gokgoz S. Evaluation of incidence and histolopathological findings of breast lesions in reduction mammoplasty specimens: Uludag University experience. J Pak Med Assoc. 2013; 63 (7): 878-881.

  18. Cook IS, Fuller CE. Does histopathological examination of breast reduction specimens affect patient management and clinical follow up? J Clin Pathol. 2004; 57 (3): 286-289.

  19. Pitanguy I, Torres E, Salgado F, Pires Viana GA. Breast pathology and reduction mammaplasty. Plast Reconstr Surg. 2005; 115 (3): 729-734; discussion 735.

  20. Ishag MT, Bashinsky DY, Beliaeva IV, Niemann TH, Marsh WL Jr. Pathologic findings in reduction mammaplasty specimens. Am J Clin Pathol. 2003; 120 (3): 377-380.

  21. Blansfield JA, Kukora JS, Goldhahn RT Jr, Buinewicz BR. Suspicious findings in reduction mammaplasty specimens: review of 182 consecutive patients. Ann Plast Surg. 2004; 52 (2): 126-130.

  22. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer. 1987; 56 (6): 814-819.

  23. Bondeson L, Linell F, Ringberg A. Breast reductions: what to do with all the tissue specimens? Histopathology. 1985; 9 (3): 281-285.




2020     |     www.medigraphic.com